SEC Company Response from Bionano Genomics, Inc. (BNGO) (CIK 0001411690) (BNGO) — Jul 27, 2018
Bionano Genomics, Inc. (BNGO) (CIK 0001411690)
Date: July 27, 2018 · CIK: 0001411690 · Accession: 0001193125-18-229597
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-225970
Letter
Re: Bionano Genomics, Inc.
VIA EDGAR
July 27, 2018
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ms. Amanda Ravitz
Registration Statement on Form S-1
File No. 333-225970
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Roth Capital Partners, LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on Tuesday, July 31, 2018, or as soon thereafter as practicable.
The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:
(i) Date of preliminary prospectus: July 19, 2018;
(ii) Dates of distribution: July 19, 2018 through the date hereof;
(iii) Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 15; and
(iv) Number of prospectuses so distributed: electronic 224, print 45.
The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
ROTH CAPITAL PARTNERS, LLC
By:
/s/ Aaron M. Gurewitz
Name:
Aaron M. Gurewitz
Title:
Head of Equity Capital Market
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR July 27, 2018 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ms. Amanda Ravitz Re: Bionano Genomics, Inc. Registration Statement on Form S-1 File No. 333-225970 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Roth Capital Partners, LLC, as representative of the underwriters, hereby requests acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on Tuesday, July 31, 2018, or as soon thereafter as practicable. The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933: (i) Date of preliminary prospectus: July 19, 2018; (ii) Dates of distribution: July 19, 2018 through the date hereof; (iii) Number of prospective underwriters and selected dealers to whom the preliminary prospectus was furnished: 15; and (iv) Number of prospectuses so distributed: electronic 224, print 45. The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue. ROTH CAPITAL PARTNERS, LLC By: /s/ Aaron M. Gurewitz Name: Aaron M. Gurewitz Title: Head of Equity Capital Market